AR066458A1 - Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. - Google Patents
Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas.Info
- Publication number
- AR066458A1 AR066458A1 ARP080101913A ARP080101913A AR066458A1 AR 066458 A1 AR066458 A1 AR 066458A1 AR P080101913 A ARP080101913 A AR P080101913A AR P080101913 A ARP080101913 A AR P080101913A AR 066458 A1 AR066458 A1 AR 066458A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- carbocyclic group
- group
- members
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicacion 1: Un compuesto de la formula (1), o tautomeros, o estereoisomeros, o solvatos, o sales farmacéuticamente aceptables de los mismos, en donde: M1 y M2 son independientemente formula (2); R1, R2, R3, y R4 se seleccionanindependientemente a partir de H, alquilo C1-8, alquilo C1-8-carboxilo, halo-alquilo C1-8, grupo carbocíclico C3-15, alquilo C1-8, alcoxilo C1-8-carbonilo, un grupo carbocíclico aromático de 6 a 15 miembros, un grupo heterocíclico C4-14, un alquiloC1-8 sustituido por un grupo heterocíclico de 4 a 14 miembros, y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15 miembros, o R1 y R2, con el átomo de nitrogeno con el que están unidos, forman un grupo heterocíclico de 3 a 14miembros opcionalmente sustituido por R14, o R3 y R4, con el átomo de nitrogeno con el que están unidos, forman un grupo heterocíclico de 3 a 14 miembros, opcionalmente sustituido por R14; L1 y L2 se seleccionan independientemente a partir deformulas (3) y (4), R6, R5, y R5a se seleccionan independientemente a partir de H, alquilo C1-8, alquilo C1-8-carboxilo, alquilo C1-8-alcoxilo, halo-alquilo C1-8, grupo carbocíclico C3-15, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, nitro,ciano, un grupo carbocíclico aromático de 6 a 15 miembros, un grupo heterocíclico de 4 a 14 miembros, un alquilo C1-8 sustituido por un grupo heterocíclico C4-14 y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15 miembros; W1y W2 se seleccionan independientemente a partir de alquileno C0-8; X1 y X2 se seleccionan independientemente a partir de un grupo heterocíclico C4-14 miembros; Y1 y Y2 son independientemente -alquileno C0-8; o alquilo C1-8-amino; A se selecciona apartir de un grupo carbocíclico aromático de 6 a 15 miembros, -CONR11a-(alquileno C1-8)-NR11aCO-, -CO-(alquileno C1-8)CO-, -CO-(alquenileno C1-8)-CO-, -C(=O), -CO-(alquileno C0-8)-Z-(alquileno C0-8)-CO-, -CONR11a(alquileno C0-8)-Z-(alquileno C0-8)-NR11aCO, grupo 10 carbocíclico C3-15, y un grupo heterocíclico de 4 a 14 miembros; Z se selecciona a partir de un grupo carbocíclico aromático de 6 a 15 miembros, grupo carbocíclico de 3 a 15 miembros, y un grupo heterocíclico de 4 a 14 miembros; Tse selecciona a partir de H, halogeno, alquilo C1-8, halo-alquilo C1-8, haloalcoxilo C1-8, grupo carbocíclico C3-15, nitro, ciano, un grupo carbocíclico aromático C6-15 y un alquilo C1-8 sustituido por un grupo carbocíclico aromático de 6 a 15miembros; en donde cada grupo carbocíclico aromático de 6 a 15 miembros, y cada grupo heterocíclico de 4 a 14 miembros o cada grupo heterocíclico de 5 a 14 miembros, a menos que se especifique de otra, está independientemente opcionalmentesustituido por uno o más grupos seleccionados a partir de OH, alcoxilo C1-8, alquilo C1-8, halogeno, SO2NR11R12, hidroxi-alcoxilo C1-8 opcionalmente sustituido por hidroxilo, (alquileno C0-4)-CONR11R12, (alquileno C0-4)-N=C(NR11R12)2, -O-(alquilenoC1-4)-N=C(NR11R12)2, -O-(alquileno C1-4)-CONR11R12, aralcoxilo C7-10, aralquilo C7-10, SH, S-(alquileno C1-8), SO2-(alquileno C1-8), SO-(alquileno C1-8), NR11R12, NR11-(grupo carbocíclico C3-12), en donde el grupo carbocíclico está opcionalmentesustituido por halogeno o alquilo C1-8, R15, un alquilo C1-8 sustituido por R15, R16, un alquilo C1-8 sustituido por R16, O-(alquileno C1-8)-NR11-(C=O)O-(alquileno C0-4)-R15, ciano, oxo, carboxilo, nitro, alquilo C1-8-carbonilo, hidroxi-alquilo C1-8, halo-alquilo C1-8, amino-alquilo C1-8, amino-(hidroxi)-alquilo C1-8, y alcoxilo C1-8 opcionalmente sustituido por amino-carbonilo, en donde R15 es un grupo carbocíclico aromático de 6 a 15 miembros, opcionalmente sustituido por OH, alcoxilo C1-8,alquilo C1-8, halogeno, y halo-alquilo C1-8, R16 es un grupo heterocíclico de 4 a 14 miembros, opcionalmente sustituido por OH, alcoxilo C1-8, alquilo C1-8, grupo carbocíclico aromático de 6 a 15 miembros, CO2H, (C=O)-grupo heterocíclico de 3 a 14miembros, halogeno, y halo-alquilo C1-8, y en donde cada grupo alquileno, a menos que se especifique de otra manera, está opcionalmente sustituido por alquilo C1-8, halogeno, alcoxilo C1-8, carboxilo, alquilo C1-8-carboxilo, halo-alquilo C1-8, halo-alcoxilo C1-8, grupo carbocíclico C3-15, alquilo C1-8-carbonilo, alcoxilo C1-8-carbonilo, nitro, ciano, R15, un alquilo C1-8 sustituido por R15, R16, o un alquilo C1-8 sustituido por R16; cada R11 y R12 se seleccionan independientemente a partir deH, alquilo C1-8, halo-alquilo C1-8, grupo carbocíclico C3-15, grupo carbocíclico aromático C6-15, y un grupo heterocíclico de 4 a 14 miembros opcionalmente sustituido por -COOH o por alquilo C1-8, o R11 y R12, junto con el átomo de nitrogeno con elque están unidos, forman un grupo heterocíclico de 5 a 14 miembros opcionalmente sustituido por CO2H, alquilo C1-8, (C=O)-grupo heterocíclico de 4 a 14 miembros, o un grupo carbocíclico aromático de 6 a 15 miembros, cuando R11 o R12 son alquilo C1-8, pueden estar opcionalmente mono- o di-sustituidos por grupo carbocíclico aromático C61-5, grupo heterocíclico de 5 a 14 miembros, alquilo C1-8-amino, OH, o un di-(alquilo C1-8)-amino opcionalmente sustituido por OH; R11a se selecciona a partir deH y alquilo C1-8; y R14 se selecciona a partir de H, halogeno, alquilo C1-8, OH, grupo carbocíclico aromático de 6 a 15 miembros, aralquilo C7-14, y O-aralquilo C7-14.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07107654 | 2007-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066458A1 true AR066458A1 (es) | 2009-08-19 |
Family
ID=38581916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101913A AR066458A1 (es) | 2007-05-07 | 2008-05-06 | Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8318935B2 (es) |
| EP (2) | EP2155721B1 (es) |
| JP (1) | JP5244904B2 (es) |
| KR (1) | KR20100005730A (es) |
| CN (1) | CN101687851B (es) |
| AR (1) | AR066458A1 (es) |
| AT (1) | ATE499363T1 (es) |
| AU (1) | AU2008248598B2 (es) |
| BR (1) | BRPI0811562A2 (es) |
| CA (1) | CA2685546A1 (es) |
| CL (1) | CL2008001301A1 (es) |
| CO (1) | CO6290667A2 (es) |
| CR (1) | CR11091A (es) |
| DE (1) | DE602008005140D1 (es) |
| EA (1) | EA200901489A1 (es) |
| EC (1) | ECSP099718A (es) |
| ES (1) | ES2361595T3 (es) |
| GT (1) | GT200900289A (es) |
| HK (1) | HK1141285A1 (es) |
| HN (1) | HN2009003214A (es) |
| IL (1) | IL201828A0 (es) |
| MA (1) | MA31400B1 (es) |
| MX (1) | MX2009012077A (es) |
| NZ (1) | NZ580737A (es) |
| PE (1) | PE20090733A1 (es) |
| PL (1) | PL2155721T3 (es) |
| PT (1) | PT2155721E (es) |
| SV (1) | SV2009003406A (es) |
| TN (1) | TN2009000469A1 (es) |
| TW (1) | TWI351402B (es) |
| WO (1) | WO2008135557A1 (es) |
| ZA (1) | ZA200907491B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| TWI432198B (zh) | 2008-02-26 | 2014-04-01 | Parion Sciences Inc | 多芳香族鈉通道阻斷劑 |
| KR20110085768A (ko) | 2010-01-21 | 2011-07-27 | 삼성전자주식회사 | Ｃｍｏｓ 이미지 센서, 상기 이미지 센서의 데이터 리드아웃 방법, 및 상기 이미지 센서를 포함하는 전자 시스템 |
| US9050339B2 (en) | 2010-09-17 | 2015-06-09 | Novartis Ag | Pyrazine derivatives as ENaC blockers |
| US8372845B2 (en) * | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| GEP20186880B (en) | 2011-11-02 | 2018-07-25 | Ingelheim International Gmbh Boehringer | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease |
| AU2012331275A1 (en) | 2011-11-02 | 2014-04-03 | Boehringer Ingelheim International Gmbh | Novel process for the preparation of acylguanidines and acylthioureas |
| US8859559B2 (en) * | 2011-12-20 | 2014-10-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
| EP2861577B1 (en) | 2012-05-25 | 2017-01-04 | Boehringer Ingelheim International GmbH | Tertiary amines, medicaments containing said amines, use thereof and processes for the preparation thereof |
| US8841309B2 (en) | 2012-09-24 | 2014-09-23 | Boehringer Ingelheim International Gmbh | Substituted pyrazines and their use in the treatment of disease |
| SG11201503365YA (en) | 2012-11-02 | 2015-06-29 | Vertex Pharma | Pharmaceutical compositions for the treatment of cftr mediated diseases |
| US9593084B2 (en) | 2012-12-17 | 2017-03-14 | Parion Sciences, Inc. | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity |
| WO2014099673A1 (en) | 2012-12-17 | 2014-06-26 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| EP2991981B1 (en) * | 2013-04-30 | 2017-03-01 | Boehringer Ingelheim International GmbH | Diaminopyrazine compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof |
| KR20160054460A (ko) * | 2013-07-02 | 2016-05-16 | 더 캘리포니아 인스티튜트 포 바이오메디칼 리써치 | 낭성 섬유증의 치료를 위한 화합물 |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| UY36034A (es) | 2014-03-18 | 2015-09-30 | Astrazeneca Ab | Derivados de 3,5-diamino-6-cloro-pirazina-2-carboxamida y sales farmaceuticamente aceptables de estos |
| JP2017508776A (ja) | 2014-03-27 | 2017-03-30 | ノバルティス アーゲー | 医薬品有効成分吸入用の噴霧乾燥した水中油中固体分散体 |
| GB201412545D0 (en) * | 2014-07-15 | 2014-08-27 | Univ Manchester The And Manchester Metropolitan University | Enzymatic processes and uses |
| CN107405505A (zh) * | 2015-01-07 | 2017-11-28 | 加州生物医学研究所 | 用于治疗囊性纤维化的化合物 |
| WO2016113169A1 (en) * | 2015-01-12 | 2016-07-21 | Boehringer Ingelheim International Gmbh | Tetra- and pentasubstituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US9932324B2 (en) * | 2015-01-12 | 2018-04-03 | Boehringer Ingelheim International Gmbh | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| EP3245199B1 (en) * | 2015-01-12 | 2020-01-01 | Boehringer Ingelheim International GmbH | Substituted benzimidazolium compounds useful in the treatment of respiratory diseases |
| US10291868B2 (en) * | 2016-01-29 | 2019-05-14 | SK Hynix Inc. | Image sensing device |
| GB201610854D0 (en) | 2016-06-21 | 2016-08-03 | Entpr Therapeutics Ltd | Compounds |
| GB201619694D0 (en) | 2016-11-22 | 2017-01-04 | Entpr Therapeutics Ltd | Compounds |
| WO2018175302A1 (en) | 2017-03-20 | 2018-09-27 | Sienna Biopharmaceuticals, Inc. | Polymer conjugates targeting c-src with reduced exposure |
| EP3600440A1 (en) | 2017-03-20 | 2020-02-05 | Sienna Biopharmaceuticals, Inc. | Reduced exposure conjugates modulating therapeutic targets |
| GB201717051D0 (en) | 2017-10-17 | 2017-11-29 | Enterprise Therapeutics Ltd | Compounds |
| GB201808093D0 (en) | 2018-05-18 | 2018-07-04 | Enterprise Therapeutics Ltd | Compounds |
Family Cites Families (117)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1219606A (en) | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
| US3544571A (en) | 1968-09-04 | 1970-12-01 | Merck & Co Inc | Process for making pyrazinoylthiourea compounds |
| US4246406A (en) | 1979-03-27 | 1981-01-20 | Merck & Co., Inc. | Heterocyclic substituted pyrazinoylguanidines |
| JPS6235216A (ja) | 1985-08-09 | 1987-02-16 | Noritoshi Nakabachi | 不均質物質層の層厚非破壊測定方法および装置 |
| GB8923590D0 (en) | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
| PT100441A (pt) | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| WO1993018007A1 (en) | 1992-03-13 | 1993-09-16 | Tokyo Tanabe Company Limited | Novel carbostyril derivative |
| WO1993019751A1 (en) | 1992-04-02 | 1993-10-14 | Smithkline Beecham Corporation | Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor |
| JP3192424B2 (ja) | 1992-04-02 | 2001-07-30 | スミスクライン・ビーチャム・コーポレイション | アレルギーまたは炎症疾患の治療用化合物 |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| TW394760B (en) * | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| GB9622386D0 (en) | 1996-10-28 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| US6166037A (en) | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| BR9815931A (pt) | 1998-06-30 | 2001-02-20 | Dow Chemical Co | Polióis poliméricos, um processo para sua produção, e espuma de poliuretanoobtida |
| GB9913083D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
| DE60021371T2 (de) | 1999-05-04 | 2006-04-27 | Schering Corp. | Piperidinderivate verwendbar als ccr5 antagonisten |
| ES2244437T3 (es) | 1999-05-04 | 2005-12-16 | Schering Corporation | Derivados de piperazina utiles como antagonistas de ccr5. |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6475509B1 (en) | 1999-07-19 | 2002-11-05 | The University Of North Carolina At Chapel Hill | Covalent conjugates of sodium channel blockers and active compounds |
| MXPA02001830A (es) | 1999-08-21 | 2002-08-12 | Byk Gulden Lomberg Chem Fab | Combinacion sinergica de inhibidores de pde y agonista de beta 2 adrenoceptor. |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| EA200201056A1 (ru) | 2000-04-27 | 2003-04-24 | Бёрингер Ингельхайм Фарма Кг | Новые, обладающие продолжительным действием бетамиметики, способ их получения и их применение в качестве лекарственных средств |
| AU6610001A (en) | 2000-06-27 | 2002-01-08 | S A L V A T Lab Sa | Carbamates derived from arylalkylamines |
| GB0015876D0 (en) | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
| DE10038639A1 (de) | 2000-07-28 | 2002-02-21 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| PT2348032E (pt) | 2000-08-05 | 2015-10-14 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-'(2-furanilcarboxil)oxi]-11.beta.-hidroxi-16.alfa.- metil-3-oxo-androsta-1,4-dieno-17-carbotióico como um agente anti-inflamatório |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| DK1345937T3 (da) | 2000-12-22 | 2006-01-16 | Almirall Prodesfarma Ag | Quinuclidincarbamatderivater og deres anvendelse som M3-antagonister |
| CZ301209B6 (cs) | 2000-12-28 | 2009-12-09 | Laboratorios Almirall, S.A. | Nové chinuklidinové deriváty a medicinální kompozice s jejich obsahem |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| CA2445839A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| WO2002100879A1 (en) | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| EP2327765B1 (en) | 2001-06-21 | 2015-04-01 | BASF Enzymes LLC | Nitrilases |
| HU228508B1 (en) | 2001-09-14 | 2013-03-28 | Glaxo Group Ltd | Phenethanolamine derivatives and pharmaceutical composition containing them |
| CA2462980A1 (en) | 2001-10-17 | 2003-04-24 | Ucb, S.A. | Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors |
| GB0125259D0 (en) | 2001-10-20 | 2001-12-12 | Glaxo Group Ltd | Novel compounds |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| TWI249515B (en) | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| WO2003048181A1 (en) | 2001-12-01 | 2003-06-12 | Glaxo Group Limited | 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents |
| JP4505227B2 (ja) | 2001-12-20 | 2010-07-21 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用 |
| AU2003202044A1 (en) | 2002-01-15 | 2003-09-09 | Glaxo Group Limited | 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents |
| WO2003062259A2 (en) | 2002-01-21 | 2003-07-31 | Glaxo Group Limited | Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents |
| GB0202216D0 (en) | 2002-01-31 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
| AU2003221706B2 (en) | 2002-04-11 | 2008-02-28 | Merck Sharp & Dohme Corp. | 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators |
| ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| WO2003099764A1 (en) | 2002-05-28 | 2003-12-04 | Theravance, Inc. | ALKOXY ARYL β2 ADRENERGIC RECEPTOR AGONISTS |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ES2201907B1 (es) | 2002-05-29 | 2005-06-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10225574A1 (de) | 2002-06-10 | 2003-12-18 | Merck Patent Gmbh | Aryloxime |
| DE10227269A1 (de) | 2002-06-19 | 2004-01-08 | Merck Patent Gmbh | Thiazolderivate |
| ES2282667T3 (es) | 2002-06-25 | 2007-10-16 | Merck Frosst Canada Ltd. | Inhibidores de pde4 8-(biaril)quinolinas. |
| ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
| WO2004005258A1 (en) | 2002-07-02 | 2004-01-15 | Merck Frosst Canada & Co. | Di-aryl-substituted-ethane pyridone pde4 inhibitors |
| DK1521733T3 (da) | 2002-07-08 | 2014-10-13 | Pfizer Prod Inc | Modulatorer af glucocorticoid receptoren |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
| WO2004018451A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Pyridazinone-derivatives as pde4 inhibitors |
| AU2003255376A1 (en) | 2002-08-10 | 2004-03-11 | Altana Pharma Ag | Piperidine-derivatives as pde4 inhibitors |
| CA2494643A1 (en) | 2002-08-10 | 2004-03-04 | Altana Pharma Ag | Piperidine-n-oxide-derivatives |
| JP4555684B2 (ja) | 2002-08-10 | 2010-10-06 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４阻害剤としての、ピロリジンジオンにより置換されたピペリジン−フタラゾン |
| US20060116518A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel phenanthridines |
| US20060113968A1 (en) | 2002-08-17 | 2006-06-01 | Altana Pharma Ag | Novel benzonaphthyridines |
| SE0202483D0 (sv) | 2002-08-21 | 2002-08-21 | Astrazeneca Ab | Chemical compounds |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| ATE423769T1 (de) | 2002-08-23 | 2009-03-15 | Ranbaxy Lab Ltd | Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten |
| US7423046B2 (en) | 2002-08-29 | 2008-09-09 | Nycomed Gmbh | 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors |
| CN1678306A (zh) | 2002-08-29 | 2005-10-05 | 贝林格尔·英格海姆药物公司 | 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物 |
| JP4587294B2 (ja) | 2002-08-29 | 2010-11-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| AU2003272879A1 (en) | 2002-09-18 | 2004-04-08 | Ono Pharmaceutical Co., Ltd. | Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient |
| JP2006096662A (ja) | 2002-09-18 | 2006-04-13 | Sumitomo Pharmaceut Co Ltd | 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| JP2004107299A (ja) | 2002-09-20 | 2004-04-08 | Japan Energy Corp | 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤 |
| DE10246374A1 (de) | 2002-10-04 | 2004-04-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| WO2004032921A1 (en) | 2002-10-11 | 2004-04-22 | Pfizer Limited | Indole derivatives as beta-2 agonists |
| EP1440966A1 (en) | 2003-01-10 | 2004-07-28 | Pfizer Limited | Indole derivatives useful for the treatment of diseases |
| JP2006506373A (ja) | 2002-10-22 | 2006-02-23 | グラクソ グループ リミテッド | 医薬アリールエタノールアミン化合物 |
| PL376769A1 (pl) | 2002-10-23 | 2006-01-09 | Glenmark Pharmaceuticals Ltd. | Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające |
| DK1556342T3 (da) | 2002-10-28 | 2008-07-21 | Glaxo Group Ltd | Phenethanolaminderivat til behandling af respiratoriske sygdomme |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225287D0 (en) | 2002-10-30 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| DE10253282A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| DE10253220A1 (de) | 2002-11-15 | 2004-05-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE10253426B4 (de) | 2002-11-15 | 2005-09-22 | Elbion Ag | Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung |
| DE10261874A1 (de) | 2002-12-20 | 2004-07-08 | Schering Ag | Nichtsteroidale Entzündungshemmer |
| EP1587818A4 (en) | 2003-01-21 | 2010-10-13 | Merck Sharp & Dohme | 17-CARBAMOYLOXY CORTISOL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| WO2004080972A1 (en) | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
| EP1460064A1 (en) | 2003-03-14 | 2004-09-22 | Pfizer Limited | Indole-2-carboxamide derivatives useful as beta-2 agonists |
| US7696244B2 (en) | 2003-05-16 | 2010-04-13 | The Regents Of The University Of California | Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof |
| GB0312832D0 (en) | 2003-06-04 | 2003-07-09 | Pfizer Ltd | 2-amino-pyridine derivatives useful for the treatment of diseases |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| JP2007535897A (ja) | 2003-06-10 | 2007-12-13 | エース バイオサイエンシズ エー／エス | 細胞外コウジカビポリペプチド |
| EP1670475A4 (en) * | 2003-08-18 | 2009-04-15 | Parion Sciences Inc | ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS |
| KR20060037450A (ko) * | 2003-08-18 | 2006-05-03 | 패리온 사이언스 인코퍼레이티드 | 사이클릭 피라지노일구아니딘 나트륨 채널 차단제 |
| US7973169B2 (en) | 2003-09-06 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| NZ546365A (en) | 2003-10-08 | 2010-01-29 | Vertex Pharma | Modulators of ATP-binding cassette transporters containing cycloalkyl or pyranyl groups |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| AU2005210474B2 (en) | 2004-01-30 | 2011-07-07 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| EP1765347A4 (en) | 2004-06-04 | 2008-10-01 | Univ California | COMPOUNDS WITH ION TRANSPORTER HEALING EFFECT BY MUTANT CFTR AND ITS USE |
| US8242149B2 (en) | 2005-03-11 | 2012-08-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2006101740A2 (en) | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | Compounds having activity in correcting mutant-cftr processing and uses thereof |
| ATE533749T1 (de) | 2005-05-24 | 2011-12-15 | Vertex Pharma | Modulatoren von atp-bindenden kassettentransportern |
| ATE512145T1 (de) | 2005-08-11 | 2011-06-15 | Vertex Pharma | Modulatoren des cystic fibrosis transmembrane conductance regulators |
-
2008
- 2008-05-05 PL PL08759419T patent/PL2155721T3/pl unknown
- 2008-05-05 MX MX2009012077A patent/MX2009012077A/es active IP Right Grant
- 2008-05-05 PE PE2008000782A patent/PE20090733A1/es not_active Application Discontinuation
- 2008-05-05 US US12/451,152 patent/US8318935B2/en not_active Expired - Fee Related
- 2008-05-05 EA EA200901489A patent/EA200901489A1/ru unknown
- 2008-05-05 EP EP08759419A patent/EP2155721B1/en active Active
- 2008-05-05 CA CA002685546A patent/CA2685546A1/en not_active Abandoned
- 2008-05-05 KR KR1020097025395A patent/KR20100005730A/ko active IP Right Grant
- 2008-05-05 AT AT08759419T patent/ATE499363T1/de active
- 2008-05-05 DE DE602008005140T patent/DE602008005140D1/de active Active
- 2008-05-05 EP EP11152559A patent/EP2332933A1/en not_active Withdrawn
- 2008-05-05 NZ NZ580737A patent/NZ580737A/en not_active IP Right Cessation
- 2008-05-05 BR BRPI0811562-1A2A patent/BRPI0811562A2/pt not_active IP Right Cessation
- 2008-05-05 JP JP2010506915A patent/JP5244904B2/ja not_active Expired - Fee Related
- 2008-05-05 PT PT08759419T patent/PT2155721E/pt unknown
- 2008-05-05 CN CN2008800226814A patent/CN101687851B/zh not_active Expired - Fee Related
- 2008-05-05 ES ES08759419T patent/ES2361595T3/es active Active
- 2008-05-05 AU AU2008248598A patent/AU2008248598B2/en not_active Ceased
- 2008-05-05 WO PCT/EP2008/055497 patent/WO2008135557A1/en active Application Filing
- 2008-05-06 TW TW097116687A patent/TWI351402B/zh not_active IP Right Cessation
- 2008-05-06 CL CL2008001301A patent/CL2008001301A1/es unknown
- 2008-05-06 AR ARP080101913A patent/AR066458A1/es not_active Application Discontinuation
-
2009
- 2009-10-26 ZA ZA200907491A patent/ZA200907491B/xx unknown
- 2009-10-29 IL IL201828A patent/IL201828A0/en unknown
- 2009-11-04 CR CR11091A patent/CR11091A/es unknown
- 2009-11-05 GT GT200900289A patent/GT200900289A/es unknown
- 2009-11-06 TN TNP2009000469A patent/TN2009000469A1/fr unknown
- 2009-11-06 CO CO09125992A patent/CO6290667A2/es not_active Application Discontinuation
- 2009-11-06 SV SV2009003406A patent/SV2009003406A/es active IP Right Grant
- 2009-11-06 HN HN2009003214A patent/HN2009003214A/es unknown
- 2009-11-06 EC EC2009009718A patent/ECSP099718A/es unknown
- 2009-11-30 MA MA32385A patent/MA31400B1/fr unknown
-
2010
- 2010-08-13 HK HK10107723.7A patent/HK1141285A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066458A1 (es) | Derivados de piperidina, procesos de obtencion y composiciones farmaceuticas. | |
| AR081831A1 (es) | Inhibidores de la proteina ns5a del virus de la hepatitis c (vhc) | |
| HRP20200752T1 (hr) | Sastavi pirolopirola kao aktivatori piruvat kinaze (pkr) | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR057871A1 (es) | Compuestos que comprenden una lactama o un resto de derivado lactamico procesos para prepararlos y sus usos.composiciones farmaceuticas. | |
| AR084388A1 (es) | Compuestos nitrogenados heterociclicos inhibidores de la replicacion del vhc y composiciones farmaceuticas que los contienen | |
| AR060658A1 (es) | Derivados de diceto-piperazina y piperidina como agentes antivirales | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR062630A1 (es) | Derivados de bipiridina sustituidos y su uso | |
| AR054814A1 (es) | Derivados de piridazina | |
| AR048537A1 (es) | Derivados de nucleosidos para tratar infecciones por virus de hepatitis c. | |
| AR055620A1 (es) | Derivados de cicloalcano-carboxamidas | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| CO6160296A2 (es) | Derivados de acido benzoazepin-oxi-acetico como agonistas de receptores activados por proliferador de peroxisona delta usados para incrementar la lipoproteina de alta densidad-colesterol-colesterol reducir la lipoproteina de baja densidad-colesterol | |
| BR112015015275A8 (pt) | composto heterocíclico substituído por halogênio, antagonista do receptor de lpa, composição farmacêutica e uso | |
| AR040335A1 (es) | Compuesto de ciclohexano o ciclohexeno, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende, procedimiento y compuestos intermediarios de utilidad para preparar dicho compuesto | |
| AR045587A1 (es) | Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen | |
| AR061840A1 (es) | Compuestos fosfinatos antivirales | |
| AR070127A1 (es) | Pirrolo - pirimidinas y pirrolo -piridinas | |
| ATE466838T1 (de) | Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer | |
| AR061220A1 (es) | Derivados de tiazol | |
| AR053770A1 (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2. composiciones farmaceuticas. | |
| WO2008148849A3 (en) | Piperidine/piperazine derivatives | |
| AR057959A1 (es) | 5-pirazolpiperidinas-(sustituidas) | |
| ECSP066947A (es) | Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |